RUNX1 and acute myeloid leukemia: Therefore, these results emphasize the need for future investigation validating the role of PLC-γ1 as potential therapeutic targets for t(8;21) AML and it showed a possibility to use a combination therapy of anti AML1-ETO with anti PLC-γ1 for t(8;21) AML.